TARSUS PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
TARSUS PHARMACEUTICALS, INC. (TARS) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value of $207.12 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue · last filed 2026-08-06
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $207.12M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $248.78M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $312.65M.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $197.11M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value |
|---|---|
| 2026-06-30 | $207.12M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $248.78M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $312.65M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $197.11M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $105.73M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $160.11M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $180.67M 10-K · filed 2026-02-23 |
| 2024-09-30 | $78.77M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $58.52M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $96.25M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $34.13M 10-K · filed 2025-02-25 |
| 2023-09-30 | $26.08M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $28.32M 10-Q · filed 2023-11-09 |
| 2023-03-31 | $15.32M 10-Q · filed 2023-11-09 |
| 2022-12-31 | $19.20M 10-K · filed 2024-02-27 |
| 2021-12-31 | $33.64M 10-K · filed 2024-02-27 |
| 2020-12-31 | $68.98M 10-K · filed 2023-03-17 |
| 2019-12-31 | $37.00K 10-K · filed 2022-03-14 |
| 2018-12-31 | $37.00K 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |